The firm said that its Vitros XT MicroSlides improve lab turnaround time by delivering simultaneous results for pairs of tests that physicians frequently order.
The firm has expansive plans, including a possible launch of 40 different types of tests. It currently plans to launch a liver function test in the US this summer.
The companies today launched four assays for the Chinese market for renal, liver, and cardiac testing for use on the Vitros 4600 and Vitros 5600 systems.
The Vitros XT MicroSlide technology allows labs to run two tests that are commonly ordered together simultaneously from a single blood sample.
The company said its testing services revenues for the quarter rose nearly 120 percent year over year.
IL said that the rapid basic metabolic panel is designed for testing at the point of care, primarily in hospital emergency departments and clinical laboratories.
The companies will develop an IVD system based on the MiniSeq initially to diagnose hereditary kidney disease.
The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.
The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.
The joint venture, called Renx AI Labs, will allow RenalytixAI to operate outside New York City and perform prospective revenue-generating contract research.